June 14, 2024 – Page 7 – Goldea Capital

HSBC Bank Plc – FORM 8.5 (EPT/RI) – Lok’n Store Group plc

Written by Customer Service on June 14, 2024. Posted in Mergers And Acquisitions.

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader: HSBC Bank Plc (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Lok’n Store Group plc (c) Name of the party to the offer with which exempt principal trader is connected: OFFEROR: Shurgard Self Storage Ltd (d) Date dealing undertaken: 13 June 2024 (e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” N/A 2. DEALINGS BY THE EXEMPT...

Zefiro Publishes “Letter from the CEO” Following its Inaugural Earnings Report

Written by Customer Service on June 14, 2024. Posted in Public Companies.

Telling the Zefiro story from its early stages in 2008 at J.P. Morgan’s offices in Manhattan, Talal Debs shares some inspirational anecdotes in Zefiro’s inaugural “Letter from the CEO”. This letter follows Zefiro’s inaugural quarterly earnings report, which reflected record revenue of USD $8.5 million for the most recent reporting quarter FORT LAUDERDALE, Fla., June 14, 2024 (GLOBE NEWSWIRE) — ZEFIRO METHANE CORP. (Cboe Canada: ZEFI) (Frankfurt: Y6B) (the “Company”, “Zefiro”, or “ZEFI”) is pleased to announce the publication of its first Letter from the CEO as a public company, following the release of its inaugural quarterly earnings report, reflecting ZEFI’s record quarter revenue of USD $8.5 million and a gross profit of USD $2.7 million (approx. 31% gross profit margin). The Letter from the CEO was sent out to Zefiro’s newsletter...

Dividend payment ex-date of Aktsiaselts Tallinna Vesi

Written by Customer Service on June 14, 2024. Posted in Dividend Reports And Estimates.

AS Tallinna Vesi (trading code TVE1T, ISIN code EE3100026436) will close the list of shareholders for dividend payment on 19 June 2024 at the end of the working day of the settlement system. Proceeding from the above, the ex-date is 18 June 2024. From that date the new owner of the shares is not entitled to dividends for the year 2023. AS Tallinna Vesi will pay dividend 0.51 euro per share. Dividends are paid out to shareholders on 27 June 2024. Taavi GröönAS Tallinna VesiCFO(+372) 62 62 200taavi.groon@tvesi.ee

RAMSAY SANTE :Cosem medical centers takeover

Written by Customer Service on June 14, 2024. Posted in Mergers And Acquisitions.

PRESS RELEASEParis, June 14th 2024 Ramsay Santé sustains the local healthcare offering, in sector 1, for more than one million patients, by taking over 11 Cosem multidisciplinary medical centres Ramsay Santé, the European leader in private hospitalization and primary care, announces the takeover of 11 Cosem medical centres. Ramsay Santé’s offer covers the existing Cosem centres in Paris, Evry, Caen, Orléans, and Marseille, which care for over 1 million patients annually in general and specialized medicine, dentistry, imaging, and laboratory analysis. The project to redeploy these centres aims to ensure the sustainability of these facilities across all present specialties and to maintain the employment of all the healthcare staff working there, totalling nearly 1,000 professionals including 660 doctors. The acquisition is fully aligned...

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Written by Customer Service on June 14, 2024. Posted in Public Companies.

Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators Preclinical safety, efficacy, and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effects MP0621 presently in IND-enabling studies with Phase 1 in AML anticipated in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced preclinical proof-of-concept data from MP0621, a multispecific cKit x CD16a x CD47 Switch-DARPin program. The data validates the Switch-DARPin...

The Enterprise Court of Nivelles approves the BioSenic restructuring plan

Written by Customer Service on June 14, 2024. Posted in Public Companies.

PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 14, 2024 7.00am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, announces that it has received the homologation judgment for the restructuring plan filed with the Enterprise Court of Nivelles. This homologation judgment makes the plan binding on all deferred creditors, and the measures provided for therein will continue until June 2029, the end of the five-year period set by law. The restructuring plan can be accessed via the following link: https://biosenic.com/sites/default/files/2024-04/PRJ_BioSenic_FR.pdf The homologation judgment closes the judicial reorganization procedure. BioSenic’s board of directors will take the necessary decisions...

WISeKey Announces Retirement of Peter Ward as Chief Financial Officer; Appoints John O’Hara as its New Chief Financial Officer

Written by Customer Service on June 14, 2024. Posted in Public Companies.

WISeKey Announces Retirement of Peter Ward as Chief Financial Officer; Appoints John O’Hara as its New Chief Financial Officer Geneva, Switzerland – June 14, 2024 – Ad-Hoc announcement pursuant to Art. 53 SIX Listing Rules – WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT), today announced the retirement of Peter Ward as its Chief Financial Officer, effective June 30, 2024. The Company appoints John O’Hara as its new Chief Financial Officer, effective July 1, 2024. Following his retirement, Mr. Ward will remain a member of the Board of Directors of WISeKey. Mr. Ward joined the Company in 2008 and has served as its Chief Financial Officer since 2015. Mr. O’Hara, who currently serves as the CFO of SEALSQ Corp. (“SEALSQ”, NASDAQ:...

Telenor Establishes New Cyber Security Company with Nordic Ambitions

Written by Customer Service on June 14, 2024. Posted in Public Companies.

Fornebu, Norway – June 14, 2024 – Norwegian businesses and public sector organisations are facing more frequent and severe cyberattacks. According to a survey conducted by Norstat, 1 in 5 business leaders reported having experienced cyberattacks in the past year – a staggering 130,000 Norwegian companies. In response to this growing threat, Telenor is establishing a new cyber security company to meet these increasing demands from businesses. “We have never experienced cyber threats as frequent and severe as we do today. The business digital landscape is under constant attack, making robust cybersecurity more critical than ever. Telenor has decided to build on its experience and expertise as one of the Norway’s strongest security players and is establishing a new cybersecurity company with Nordic ambitions,” says Sigve Brekke, CEO...

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

Written by Customer Service on June 14, 2024. Posted in Public Companies.

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of its previously announced underwritten public offering of an aggregate of 11,250,000 shares of its common stock at an offering price of $4.00 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,750,000 shares of common stock at an offering price of $3.999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and other...

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

Written by Customer Service on June 14, 2024. Posted in Public Companies.

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a public offering price of $1.35 per share and (ii) pre-funded warrants to purchase 1,031,602 shares of common stock in lieu of shares of common stock to certain investors. The pre-funded warrants will be immediately exercisable, and may be exercised at any time after their original issuance. The purchase price of each pre-funded warrant sold in the offering will be equal to the price at which a share of common stock is sold in the offering, minus $0.0001, and the exercise price of each pre-funded warrant will equal $0.0001 per share. In connection with the offering, Gain has granted the underwriter a 30-day...

Day: June 14, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice